Ultragenyx Cuts 20% of Staff, Reaffirms 2027 Profitability After $210M PRV Close
RARE sits 28% above its 52-week low of $12.73.
Summary
Ultragenyx reported $173 million of Q3 revenue, closed the $210 million PRV sale, and is cutting about 20% of its workforce to reach GAAP profitability in 2027.
Key Events · Earnings and Guidance · RARE
-
Q3 Revenue Grows to $173M
Total revenue rose to $173 million from $160 million a year earlier, with CRYSVITA at $109 million and DOJOLVI at $30 million. Net loss narrowed to $118 million, or $1.16 per share, from $180 million.
-
20% Workforce Reduction Announced
The restructuring cuts about 20% of employees to roughly 1,000 and carries about $25 million in severance and related charges, mostly in Q4 2026, with the reduction substantially complete by year-end.
-
2027 Expense Targets Set
Management targets 2027 R&D below $350 million and SG&A below $375 million, at least a 50% reduction in R&D versus 2025, and reaffirms full-year GAAP profitability in 2027.
-
$210M PRV Sale Closed
The GENGLYCOS priority review voucher sale closed October 30, 2026 for $210 million gross, with 20% payable to the NIH. The separate $203 million FAYUVI PRV sale is expected to close later this month, for about $350 million of combined net proceeds.
Analysis · RARE · Life Sciences
Ultragenyx is trading near-term growth spending for a profitability promise. The company closed the $210 million GENGLYCOS PRV sale (about $168 million net after the 20% NIH share) and is cutting roughly 20% of its workforce, leaving about 1,000 employees, at a cost of about $25 million in severance and related charges. Those cuts underpin 2027 R&D below $350 million and SG&A below $375 million, at least a 50% reduction in R&D versus 2025, and management reaffirmed full-year GAAP profitability in 2027. The trade-off is real: UX701 for Wilson disease is terminated and all GTX-102 Angelman studies are being wound down, so the pipeline narrows to GENGLYCOS and FAYUVI launches plus DTX301 data expected in the first half of 2027. With $401 million of cash and $43 million burned in the quarter, the PRV proceeds plus the second $203 million FAYUVI PRV sale expected to close this month are what fund the plan.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $16.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.73 to $39.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.